All
Zynyz Plus Chemo Combo Improves Survival in Recurrent/Metastatic SCAC
Adding Zynyz to carboplatin and paclitaxel prolonged survival without progression in chemotherapy-naive recurrent or metastatic squamous cell carcinoma of the anal canal.
TILs May Predict Survival in Early HER2-Positive Breast Cancer Treated With Herceptin
High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment.
Lenvima Regimen Offers Benefits in Intermediate Stage Liver Cancer
Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial chemoembolization.
Survival, Progression Improves With Xofigo Plus Xtandi for Certain Patients With Prostate Cancer
Patients with metastatic, castration-resistant prostate cancer saw significant benefits from the combination of Xofigo and Xtandi.
Keytruda Plus Chemoradiotherapy May Represent New Standard of Care in Cervical Cancer Subset
Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated with Keytruda plus chemoradiotherapy.
Postsurgical Keytruda Plus Chemo May Benefit Patients With dMMR Endometrial Cancer
Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among patients with high-risk endometrial cancer.
Rybrevant Plus Chemo Results in Superior Outcomes in EGFR-Mutant Advanced NSCLC
Rybrevant plus chemotherapy improved overall survival versus chemo alone in EGFR-mutant advanced non-small cell lung cancer after disease progression.
Enhertu Demonstrates Overall, Intracranial Activity in HER2-Positive Breast Cancer
Patients with HER2-positive breast cancer benefitted from treatment with Enhertu regardless of brain metastasis.
Welireg Shows Stable Survival Benefits Over Afinitor in Kidney Cancer
Among patients with previously treated advanced clear cell renal cell carcinoma (RCC) Welireg continued to show some benefits, though not to overall survival.
Imfinzi After Primary Treatment Does Not Improve Disease-Free Survival in PD-L1-Positive NSCLC
Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.
A Lesson About Mindset I Learned Overcoming a Less than 10% Survival Rate
Looking back at my experience with osteosarcoma, I realized that managing the mental game was half the battle, especially with so much negativity.
Princess Kate Finishes Chemo, E Street Band Member Announces Diagnosis and More
From Princess Kate entering ‘a new phase of recovery’ to a Rock and Roll Hall of Famer’s blood cancer announcement, here’s what’s happening in the cancer space this week.
Steering the Treatment of Gynecologic Cancers With Biomarkers
Several drug classes, including immunotherapy, antibody-drug conjugates and PARP inhibitors have helped improve outcomes for gynecologic cancers.
FDA Approves Subcutaneous Tecentriq Formulation
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.
Darzalex Regimen Boosts Rates of MRD Negativity in Newly Diagnosed, Transplant-Eligible Myeloma
A Darzalex-based regimen improved MRD negativity rates compared with VRd in patients with newly diagnosed, transplant-eligible multiple myeloma.
Why Biomarkers Are a ‘Double-Edged Sword’ for Patients and Providers
As part of the CURE® Educated Patient® Gynecologic Cancers Summit, an expert explained the basics of biomarkers and the questions they raise.
How I Found Out About My Breast Cancer Diagnosis
Receiving a diagnosis of breast cancer was one of the more traumatic moments I’ve experienced, but the way I found out added to that.
Choices About Cancer Treatment During a Tumultuous Time
In this Fall issue of CURE, we focus on AYAs with cancer, latest treatments in small cell lung cancer, preparing for a virtual visit and answering common questions about breast cancer.
Frontline Ivonescimab May Further Reduce Progression or Death Risk Versus Keytruda in NSCLC Subset
Some patients with non-small cell lung cancer saw a 49% reduction in the risk of disease progression or death with ivonescimab versus Keytruda.
Opdivo Before and After Surgery Lowers Risk of Recurrence or Death by 40% in NSCLC
Patients with non-small cell lung cancer saw a reduction in their risk of recurrence or death after surgery when treated with pre- and postsurgical Opdivo.
Navigating Clinical Trials in Gynecologic Cancers
Patients can benefit from clinical trials in gynecologic cancers, and knowing that they can advocate for themselves for potential consideration for study enrollment.
Dealing With the Uncertainty of Cancer
Since my diagnosis with multiple myeloma, I try to keep inspired to keep moving forward despite the challenges.
A New Era in Small Cell Lung Cancer Treatment
Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer.
Adcetris Plus Revlimid and Rituxan Continues to Improve Relapsed/Refractory Diffuse Large B-Cell Lymphoma Results
Adcetris plus Revlimid/Rituxan significantly improved outcomes versus Revlimid/Rituxan alone in relapsed/refractory lymphoma.
First-Line Rybrevant Plus Lazcluze Shows Trend Toward Overall Survival in EGFR-Positive NSCLC
Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer.
‘Never Give Up’: Treatment Breakthroughs Arrive for SCLC
With pivotal trial results and an approval from the FDA, the landscape is changing for patients with small cell lung cancer.
Yes, You Can Donate Many Unused Cancer Drugs
A patient with metastatic breast cancer confronts financial toxicity and finds a little glimmer of hope through donating cancer drugs.
Pros and Cons of Surgery Approaches in Gynecologic Cancers
Surgery for gynecologic cancers is a common form of treatment, but each surgical approach has its advantages and disadvantages for patients.
Xtandi Offers Small Benefits Over Zytiga in Advanced Prostate Cancer
Researchers have compared Xtandi and Zytiga head-to-head in the treatment of metastatic castration-resistant prostate cancer.
Understanding Molecular Classifications of Gynecologic Cancers
After being diagnosed with a type of gynecologic cancer, it is essential for patients to understand the molecular makeup of their disease.